🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Rebecca J. Nagy

ORCID: 0000-0002-6778-6891

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial”.

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30169-8

N/A

5.1DataRank · unranked

360 citations

Steven B. Maron, Walid K. Chatila, Brittanie M Millang, Shweta S. Chavan, Carly Alterman +20 more

Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.05.021

N/A

0.646DataRank · unranked

73 citations

Victoria M. Raymond, Richard B. Lanman, Jacqulyne Robichaux, Junqin He, Monique B. Nilsson +17 more

Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4559

N/A

0.292DataRank · unranked

6 citations

Walid K. Chatila, Brittanie M Millang, Shalom Sabwa, Joanne F. Chou, Lilan Ling +15 more

Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4058

N/A

0.165DataRank · unranked

2 citations

Walid K. Chatila, Henry Walch, Ryan Ptashkin, Shalom Sabwa, Lilan Ling +13 more

A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.tps270

N/A

0DataRank · unranked

3 citations

Donna Niedzwiecki, Christy Arrowood, Nancy Garett-Mead, Rebecca J. Nagy, Richard B. Lanman +4 more